JP2015533510A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533510A5
JP2015533510A5 JP2015539817A JP2015539817A JP2015533510A5 JP 2015533510 A5 JP2015533510 A5 JP 2015533510A5 JP 2015539817 A JP2015539817 A JP 2015539817A JP 2015539817 A JP2015539817 A JP 2015539817A JP 2015533510 A5 JP2015533510 A5 JP 2015533510A5
Authority
JP
Japan
Prior art keywords
retrovirus
promoter
cancer
pharmaceutical composition
retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015539817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533510A (ja
JP6419706B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066709 external-priority patent/WO2014066700A1/en
Publication of JP2015533510A publication Critical patent/JP2015533510A/ja
Publication of JP2015533510A5 publication Critical patent/JP2015533510A5/ja
Application granted granted Critical
Publication of JP6419706B2 publication Critical patent/JP6419706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015539817A 2012-10-25 2013-10-24 ミニプロモーターカセットを含むレトロウイルスベクター Expired - Fee Related JP6419706B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718610P 2012-10-25 2012-10-25
US61/718,610 2012-10-25
PCT/US2013/066709 WO2014066700A1 (en) 2012-10-25 2013-10-24 Retroviral vector with mini-promoter cassette

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018128726A Division JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター

Publications (3)

Publication Number Publication Date
JP2015533510A JP2015533510A (ja) 2015-11-26
JP2015533510A5 true JP2015533510A5 (enExample) 2016-11-10
JP6419706B2 JP6419706B2 (ja) 2018-11-07

Family

ID=50545284

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015539817A Expired - Fee Related JP6419706B2 (ja) 2012-10-25 2013-10-24 ミニプロモーターカセットを含むレトロウイルスベクター
JP2018128726A Pending JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター
JP2020136906A Pending JP2021006031A (ja) 2012-10-25 2020-08-14 ミニプロモーターカセットを含むレトロウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018128726A Pending JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター
JP2020136906A Pending JP2021006031A (ja) 2012-10-25 2020-08-14 ミニプロモーターカセットを含むレトロウイルスベクター

Country Status (6)

Country Link
US (1) US11065311B2 (enExample)
EP (2) EP2909324B1 (enExample)
JP (3) JP6419706B2 (enExample)
CN (1) CN104884627A (enExample)
ES (1) ES2786051T3 (enExample)
WO (1) WO2014066700A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
EA201890640A1 (ru) * 2015-09-04 2018-09-28 Токаджен Инк. Рекомбинантные векторы, содержащие пептид 2а
CN108474003A (zh) * 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
ES2939617T3 (es) * 2015-11-24 2023-04-25 Glaxosmithkline Ip Dev Ltd Líneas celulares estables para producción retroviral
CN110225977B (zh) 2016-11-29 2023-05-05 阿迪雷尔有限公司 基因治疗载体系统和药物前体基因
KR20240024326A (ko) 2017-05-19 2024-02-23 엔코디드 테라퓨틱스, 인크. 고활성 조절 요소
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN111727259B (zh) 2017-12-01 2024-04-19 编码治疗公司 工程化的dna结合蛋白
GB201720948D0 (en) * 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
WO2020102437A1 (en) * 2018-11-13 2020-05-22 Tocagen Inc. Recombinant vectors comprising genes for binding domains and secretable peptides
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
EP4096670A4 (en) * 2020-01-30 2024-02-28 Purdue Research Foundation LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THEIR USES
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之pd-l1結合多肽
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN116334010B (zh) * 2023-05-30 2023-08-29 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5997859A (en) 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
DE68921034D1 (de) 1988-09-27 1995-03-23 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
WO1993003143A1 (en) 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU688292B2 (en) 1992-11-09 1998-03-12 United States Government as represented by the Department of Health and Human Services, The Targetable vector particles
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
JPH08511156A (ja) 1993-04-06 1996-11-26 アメリカ合衆国 テナガザル白血球ウイルスベースのレトロウイルスベクター
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
AU708972B2 (en) 1994-11-07 1999-08-19 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
GB9604354D0 (en) 1996-02-29 1996-05-01 Isis Innovation Targeting adapters
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
ES2316153T3 (es) 1996-08-16 2009-04-01 Human Genome Sciences, Inc. Endoquina alfa humana.
US6025192A (en) 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
BR9612752A (pt) 1996-10-25 2000-01-18 Human Genome Sciences Inc Neutrocina
ATE321855T1 (de) 1997-01-14 2006-04-15 Human Genome Sciences Inc Tumor-nekrose-faktor rezeptor 5
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
WO1998054202A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
WO1999020742A2 (en) 1997-10-20 1999-04-29 Universita' Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
AU758155B2 (en) 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
FR2778670B1 (fr) 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US6448390B1 (en) 1998-05-20 2002-09-10 The University Of Tennessee Research Corporation Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
DE69940521D1 (de) * 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
GB0122803D0 (en) * 2001-09-21 2001-11-14 Oxford Biomedica Ltd Vector
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
CA2371946A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
EP1059356B1 (en) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replicating retroviral constructs, preparation and uses for gene delivery
EP1059357A1 (en) 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery
GB2368846B (en) * 1999-07-08 2004-08-25 Univ California Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
WO2001040488A1 (en) 1999-11-30 2001-06-07 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6322696B1 (en) 2000-02-25 2001-11-27 Gp Companies, Inc. Inlet filter for high pressure sprayer
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU2001292711A1 (en) 2000-09-18 2002-03-26 Genetic Therapy, Inc. Stress resistant retroviruses
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US20030003565A1 (en) 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2004532039A (ja) 2001-03-26 2004-10-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ヘルパー依存性アデノウイルスベクター系およびその系の使用方法
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
JP2005510491A (ja) 2001-10-26 2005-04-21 イミュノ−アールエックス, インコーポレイテッド 免疫抑制を逆転させるための免疫治療
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
AU2003206815A2 (en) 2002-02-01 2003-09-02 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with PODs
CA2524892A1 (en) 2002-05-17 2003-11-27 Retrovec Aps A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof
MXPA05000647A (es) 2002-07-17 2005-03-31 Squibb Bristol Myers Co Mamiferos no humanos transgenicos que expresan un acido nucleico reportero bajo regulacion de los elementos de respuesta de androgenos.
EP1534847B1 (en) 2002-09-03 2015-10-28 Oxford Biomedica (UK) Limited Retroviral vector and stable packaging cell lines
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
BRPI0515735A2 (pt) 2004-11-04 2011-10-11 Pfizer Prod Inc tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos
AU2005309485A1 (en) 2004-11-24 2006-06-01 Nanovector Limited Viral vectors
US20060147429A1 (en) 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
US20070048285A1 (en) 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector
WO2007036233A2 (en) 2005-09-30 2007-04-05 Zgene A/S Dekkera/brettanomyces cytosine deaminases and their use
EP2386564B1 (en) 2005-10-01 2014-07-16 Charles Stout Regulatable fusion promoters
WO2007044483A2 (en) 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
SI2012816T1 (sl) 2006-05-02 2012-09-28 Sigma Tau Ind Farmaceuti Uporaba timozina 1, samega ali v kombinaciji s PTX3 ali ganciklovirjem, za zdravljenje citomegalovirusne infekcije
SG173337A1 (en) 2006-07-21 2011-08-29 California Inst Of Techn Targeted gene delivery for dendritic cell vaccination
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
WO2010036986A2 (en) 2008-09-26 2010-04-01 Tocagen Inc. Recombinant vectors
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
SG176890A1 (en) 2009-06-17 2012-01-30 Tocagen Inc Producer cells for replication competent retroviral vectors
AU2011289283B2 (en) * 2010-08-13 2015-04-30 Pioneer Hi-Bred International, Inc. Chimeric promoters and methods of use
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
KR101888391B1 (ko) 2014-09-01 2018-08-14 삼성전자 주식회사 음성 신호 관리 방법 및 이를 제공하는 전자 장치

Similar Documents

Publication Publication Date Title
JP2015533510A5 (enExample)
US11065311B2 (en) Retroviral vector with mini-promoter cassette
US20220195460A1 (en) Retroviral vector having immune-stimulating activity
JP5265643B2 (ja) 免疫治療組成物調製用のレンチウイルスベクター
CN1058993C (zh) 用于癌症治疗的分子嵌合体的制备方法及应用
JP2012503987A5 (enExample)
ES2709481T3 (es) Vectores recombinantes
JP2016526920A5 (enExample)
JP2012503986A5 (enExample)
JP2018526007A (ja) 2aペプチドを含む組換えベクター
JP2016526920A (ja) 最適化a−バルジを有する組換えベクター
AU2011278931A1 (en) Targeted nanoparticles for cancer and other disorders
JP2007075121A (ja) 条件致死遺伝子を利用する組成物及び方法
US20070178066A1 (en) Pathotropic targeted gene delivery system for cancer and other disorders
CN109072253B (zh) 包含GM-CSF基因、Flt3L-TRAIL融合基因、抑制TGF-β表达的shRNA和抑制HSP表达的shRNA的抗肿瘤组合物
Olbrich et al. Reconstructing the immune system with lentiviral vectors
JP4343708B2 (ja) 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
US20160222412A1 (en) Recombinant vector with stabilizing a-loop
US20240167038A1 (en) RNA Trans-Splicing Molecule
Metzl Tissue-and tumour-selective targeting of murine leukemia virus-based replication-competent retroviral vectors
Ghaneh 9 Novel Alternatives to Chemotherapy in Advanced